Rationale: Circulating levels of endothelin (ET)-1 and endogenous ET A -mediated constriction are increased in human aging. The mechanisms responsible are not known. Objective: Investigate the storage, release, and activity of ET-1 system in arteries from young and aged Fischer-344 rats. Methods and Results: After NO synthase inhibition (L-NAME), thrombin contracted aged arteries, which was inhibited by endothelial denudation, ET A receptor antagonism (BQ123), and ECE inhibition (phosphoramidon, SM19712) or by inhibiting exocytosis (TAT-NSF, N-ethylmaleimide-sensitive factor inhibitor). Thrombin did not cause endothelium-dependent contraction of young arteries. In aged but not young arteries, thrombin rapidly increased ET-1 release, which was abolished by endothelium denudation or TAT-NSF. L-NAME did not affect ET-1 release. ET-1 immunofluorescent staining was punctate and distinct from von Willebrand factor (VWF). VWF and ET-1 immunofluorescent intensity was similar in young and aged quiescent arteries. Thrombin rapidly increased ET-1 staining and decreased VWF staining in aged but had no effect in young aortas. After L-NAME, thrombin decreased VWF staining in young aortas. NO donor DEA-NONOate (1 to 100 nmol/L) reversed thrombin-induced exocytosis in young (VWF) but not aged L-NAME-treated aortas (VWF, ET-1). Expression of preproET-1 mRNA and ECE-1 mRNA were increased in aged compared to young endothelium. BigET-1 levels and contraction to exogenous BigET-1 (but not ET-1) were also increased in aged compared to young arteries. Conclusions: The stimulated exocytotic release of ET-1 is dramatically increased in aged endothelium. This reflects increased reactivity of exocytosis, increased expression and storage of ET-1 precursor peptides, and increased expression of ECE-1. Altered endothelial exocytosis of ET-1 and other mediators may contribute to cardiovascular pathology in aging. (Circ Res. 2010;107:242-251.) 
H uman aging is associated with an increase in baseline systemic vasoconstriction and increased circulating levels of endothelin (ET)-1. [1] [2] [3] [4] Indeed, inhibition of ET A receptors causes powerful vasodilation in aged but not young individuals 5, 6 and normalizes the reduced blood flow and increased vascular resistance in elderly subjects. 5 Constriction to exogenous ET-1 appears diminished in the elderly suggesting that the increased activity of ET-1 reflects the increased levels of the mediator. 6 Increased ET-1 production can cause oxidant stress, endothelial dysfunction, vascular inflammation and vascular remodeling, and likely contributes to age-related cardiovascular dysfunction. [7] [8] [9] Indeed, ET-1 contributes to stiffening and calcification of central arteries, 10 -14 which is a prominent characteristic of the aging vascular system and is associated with increased risk for stroke, myocardial infarction, heart failure and mortality in the elderly. 15 ET-1 is the major vascular ET isoform and is produced predominantly by the endothelium. 9, 16 In cultured endothelial cells, ET-1 is released continuously through a constitutive pathway that is regulated principally through gene transcription and translation. 9, 16 However, stimulation of cultured endothelial cells also causes a rapid increase in ET-1, which suggests storage of ET-1 or its precursors and regulated exocytosis. 17 Indeed, ET-1 has been localized to Weibel-Palade bodies (WPBs), the most recognizable endothelial storage granule, although the primary localization in cultured and native endothelium may be in distinct storage granules. [17] [18] [19] [20] [21] [22] This pattern of partial localization in WPBs is similar to other endothelial mediators, including tissue plasminogen activator. [23] [24] [25] [26] ET-1 is formed from precursor peptides by proteolytic processing. PreproET-1 mRNA is translated, stripped of its signal sequence and further cleaved by a furin-like peptidase to generate BigET-1. 9, 16 Further process-ing to biologically active ETs is achieved predominantly by endothelin-converting enzyme (ECE). 9, 16 Despite the evidence for increased activity of ET-1 in the aging vascular system, no previous studies have directly analyzed the exocytotic release of ET-1 from aging endothelial cells. Therefore, the present experiments were performed to investigate the ET-1 signaling system in aging native arterial endothelium.
Methods
Young (3 to 4 months) and aged (18 to 20 months) Fischer-344 rats were used in the study, which was approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University and complied with the NIH Guide for the Care and Use of Laboratory Animals. Thoracic aorta and mesenteric arteries were rapidly and carefully removed from anesthetized rats into cold physiological buffer solution. Tissues were processed for measurement of vasomotor activity or endothelial mediator expression and release by ELISA, laser scanning microscopy and real-time PCR.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

Endothelium, ET-1, and Thrombin-Induced Contractions
Aortas
In aged aortas, thrombin (1 U/mL) caused a transient dilation that peaked at 37.7Ϯ5.9% (nϭ6) of the contraction to phenylephrine (Figure 1 ). After NO synthase (NOS) inhibition (L-NAME, 100 mol/L), the relaxation to thrombin (1 U/mL) was abolished and converted to rapid contraction ( Figure 1 ). In endothelium-denuded arteries (with or without L-NAME), thrombin (1 U/mL) caused only a small contractile response, suggesting that the transient dilation and the major component of the contraction to thrombin were mediated by the endothelium (Figure 1 and Online Figure I ). Although the selective ET A receptor antagonist BQ123 (1 mol/L) did not affect the transient dilation to thrombin, it markedly reduced the contraction to thrombin in L-NAMEtreated aged aortas ( Figure 1 ). The inhibitory effect of BQ123 in L-NAME-treated aged aortas was similar to the inhibitory effect of endothelial denudation ( Figure 1 ). The ET B receptor antagonist BQ788 (1 mol/L, alone or in presence of BQ123) did not affect contractions to thrombin in aged L-NAMEtreated aortas (Online Figure II) .
In young aortas, thrombin (1 U/mL) caused relaxation that was greater in magnitude and was more sustained than in aged blood vessels (69.9Ϯ6.0% of the contraction to phenylephrine, nϭ5, PϽ0.01 compared to aged arteries) ( Figure  1 ). As in aged aortas, NOS inhibition (L-NAME, 100 mol/L) abolished the relaxant response to thrombin and converted it to contraction ( Figure 1 ). However, the contractile response to thrombin in young aortas was not affected by ET receptor antagonism (BQ123 [1 mol/L] and/or BQ788 [1 mol/L]) or by endothelial denudation (Figure 1 and Online Figure II) .
Exogenous ET-1 (in the presence of L-NAME, 100 mol/L), caused similar concentration-dependent contractions of young and aged aortas that were virtually abolished by the ET A receptor antagonist BQ123 (1 mol/L) (Online Figure III) .
Mesenteric Arteries
In control quiescent arteries, thrombin (1 U/mL) did not affect the baseline diameter of young or aged mesenteric arteries. However, in the presence of L-NAME (100 mol/L), thrombin (1 U/mL) caused constriction that was significantly increased in aged compared to young arteries (Online Figure IV) .
In aged L-NAME-treated arteries, thrombin-induced constriction was markedly reduced by endothelial denudation or by antagonism of ET A and ET B receptors (BQ123 [1 mol/L], BQ788 [1 mol/L]) (Online Figure IV) . Constriction to phenylephrine was not significantly affected by these interventions (Online Figure IV) .
The small constriction to thrombin in young L-NAMEtreated arteries was not affected by endothelial denudation or by antagonism of ET A and ET B receptors (BQ123 [1 mol/L], BQ788 [1 mol/L]) (Online Figure IV) .
Exogenous ET-1 caused similar concentration-dependent constrictions of young and aged L-NAME-treated mesenteric arteries that were virtually abolished by antagonism of ET A and ET B receptors (BQ123 [1 mol/L], BQ788 [1 mol/L]) (Online Figure V) .
Endothelial Exocytosis and Thrombin-Induced Contractions
TAT-NSF is a cell-permeable inhibitor of endothelial exocytosis that acts by blocking the activity of NSF (Nethylmaleimide-sensitive factor), a critical component of the exocytotic machinery. 27, 28 In aged rat aortas treated with L-NAME (100 mol/L), the endothelium-dependent contrac- 
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ET-1 Release and Aging Endothelium
In aged aortas, thrombin (1 U/mL, 5 minutes) caused a rapid 3.7-fold increase in ET-1 release that was prevented by endothelial denudation or by the exocytosis inhibitor TAT-NSF (1 mol/L), but not affected by the control peptide (TAT-CON) ( Figure 3 ). Inhibition of NOS (L-NAME, 100 mol/L) did not significantly affect ET-1 release under basal conditions or in response to thrombin in aged aortas ( Figure 3 ). In young aortas, thrombin did not affect ET-1 release in the presence or absence of L-NAME ( Figure 3 ). The basal release Figure 1 . Thrombin-induced vasomotor responses in aged and young rat aortas. Responses to thrombin (1 U/mL) were assessed in aortic rings contracted with phenylephrine in the absence or presence of the ET A antagonist BQ123 (1 mol/L) and/or the NOS inhibitor L-NAME (100 mol/L) and in endotheliumdenuded rings (EϪ). Upper trace is a representative experiment in aged aortas, whereas the lower graphs present combined data for aged (top) or young aortas (bottom). Responses to thrombin were determined after 5 minutes, expressed as a percentage change in the contraction to phenylephrine and presented as meansϮSEM for nϭ3 to 6. *Significant difference from control (**PϽ0.01; ***PϽ0.001); #significant difference from L-NAME-treated aortas (#PϽ0.05; ##PϽ0.01).
Figure 2. Effect of TAT-NSF, a cell-permeable inhibitor of endothelial exocytosis on endothelium-dependent contractions to thrombin (1 U/mL) in aged rat aorta.
Thrombininduced contraction was assessed in aortic rings, which were treated with the NOS inhibitor L-NAME (100 mol/L) and contracted with phenylephrine, in the absence or presence of TAT-NSF or a control scrambled peptide TAT-CON (each at 1 mol/L). Responses to thrombin were determined after 5 minutes, expressed as a percentage change in the contraction to phenylephrine and presented as meansϮSEM for nϭ5. #Significant difference from L-NAME-treated aortas (PϽ0.05).
Figure 3. Analysis of the release of ET-1 from aged and young rat aortas.
Release of ET-1 from aortic segments (upper: aged; lower: young) was determined under basal conditions and following stimulation with thrombin (1 U/mL, 5 minutes) in the absence or presence of the NOS inhibitor L-NAME (100 mol/L), the inhibitor of exocytosis (TAT-NSF), or a control scrambled peptide (TAT-CON) (each at 1 mol/L) and in endothelium-denuded rings (EϪ). ET-1 levels were determined by ELISA, expressed relative to basal unstimulated conditions, and presented as meansϮSEM for nϭ4 to 5. *Significant difference from control (C) (*PϽ0.05,**PϽ0.01; ***PϽ0.001); #significant difference from thrombin (THR)-treated aortas, PϽ0.05.
of ET-1 was not significantly different between young and aged aortas (111.4Ϯ23.7 and 87.1Ϯ20.1 pg/g dry tissue, respectively, nϭ5, PϭNS). Figure VI ). ET-1 immunofluorescence revealed punctate staining in the endothelium that was distinct from WPBs ( Figure 4 ). Under control unstimulated conditions, there was no significant difference in the intensity of VWF or of ET-1 staining between young and aged endothelium ( Figure 5 ). Thrombin (1 U/mL, 5 minutes) did not significantly affect ET-1 or VWF staining in young control aortas ( Figure 5 ). However, thrombin (1 U/mL, 5 minutes) significantly increased ET-1 immunofluorescence and decreased VWF immunofluorescence associated with the endothelium of aged control aortas ( Figure 5 ). Acute inhibition of ECE (SM19712, 200 mol/L 30 minutes before thrombin) prevented the thrombin-induced increase in ET-1 immunofluorescence but not the thrombin-induced decrease in VWF immunofluorescence in aged aortas ( Figure 6 ).
Imaging ET-1 and WPBs in Native Endothelium
Although thrombin had no significant effect on WPBs in young control aortas, in the presence of L-NAME (100 mol/L) thrombin caused a dramatic mobilization of these endothelial storage granules, evidenced by the presence of VWF immunofluorescent aggregates and strands (Online Figure VII) and by a significant decrease in intensity of VWF fluorescence (Figure 7) . In aged arteries, the effect of throm-bin was not influenced by the presence of L-NAME (Online Figure VII ; Figures 5 and 7) .
The effects of the NO donor DEA-NONOate were analyzed in L-NAME-treated aortas. DEA-NONOate (0.1 to 100 nmol/L) caused similar relaxation of aged and young aortas contracted with phenylephrine ( Figure 7A ). However, in aged arteries, DEA-NONOate (1 to 100nmol/L) did not significantly affect the stimulation of endothelial exocytosis by thrombin (1 U/mL), which was characterized by increased fluorescent staining for ET-1 ( Figure 7B ) and decreased fluorescent staining for VWF ( Figure 7C ). In contrast, DEA-NONOate (1 to 100 nmol/L) significantly reversed the thrombin-induced decrease in VWF staining in young arteries ( Figure 7C ). Thrombin (1 U/mL) did not affect ET-1 immunofluorescence in young L-NAME-treated aortas ( Figure 7B ).
Processing of ET-1 in Young and Aging Arteries
In aged L-NAME-treated aortas, the rapid contraction to thrombin (1 U/mL) was inhibited by acute treatment with ECE inhibitors SM19712 (200 mol/L) or phosphoramidon (30 mol/L) (each 30 minutes before thrombin), which caused similar inhibition as the ET A receptor antagonist BQ123 (Online Figure VIII) . The ECE inhibitors did not affect the contractile response to thrombin in young aortas (Online Figure VIII) .
Analysis of aortic lysates revealed a 3.2-fold increase in the ET-1 precursor Big ET-1 in aged compared to young blood vessels ( Figure 8A) , which was associated with increased expression of preproET-1 mRNA in aged aortas ( Figure 8C ). Endothelial denudation reduced the aortic expression of preproET-1 mRNA and abolished the difference in expression between young and aged blood vessels.
Expression of ECE-1 mRNA was also increased in aged compared to young aorta ( Figure 8C ). Endothelial denudation reduced the expression of ECE-1 mRNA in aged aortas and abolished the difference in expression between young and aged blood vessels ( Figure 8C ). ECE-2 expression was similar in aged and young aortas ( Figure 8C ). Consistent with increased ECE-1 expression, the ET-1 precursor, BigET-1 (30 nmol/L) caused contraction that was significantly greater in aged compared to young aortas ( Figure 8B ). The ECE inhibitor phosphoramidon (30 mol/L) decreased the contraction to BigET-1 in young and aged arteries, and after phosphoramidon, there was no longer any significant difference between young and aged aortas ( Figure 8B ).
Discussion
The results of the present study demonstrate that ET-1 is generated during stimulated endothelial exocytosis in aged but not in young arteries and that this ET-1 contributes to constriction of the aged vascular system. ET-1 was formed predominantly and rapidly during the exocytotic process. An aging-associated specific increase in the stimulated generation of ET-1 reflects increased expression and storage of ET-1 precursors and increased expression of ECE-1 in aged endothelium. Stimulated exocytosis from aged endothelium was also less sensitive to inhibition by NO compared to young arteries, and so an important restraint on endothelial exocytosis is diminished. The increased ability of aged endothelium to generate ET-1, combined with an increased excitability of the exocytotic process may contribute to the cardiovascular pathology of aging.
Endothelial secretagogues such as thrombin can cause rapid release of mediators from distinct storage granules in cultured endothelial cells, as well as de novo synthesis of endothelial vasodilators including NO. 24, 29, 30 Indeed, thrombin caused NOS and endothelium-dependent relaxation, which was decreased in aged compared to young aortas. This is consistent with the known effect of aging to decrease endothelium-dependent relaxation and NO activity. [31] [32] [33] After NOS inhibition, the thrombin response converted to rapid contraction, which was increased in aged compared to young arteries. The aging-dependent increase in thrombin-induced contraction was entirely dependent on the endothelium (absent in endothelium-denuded arteries) and was prevented by blocking ET receptors. Studies on cultured endothelial cells have suggested that ET-1 release can occur through two processes: a constitutive pathway regulated principally through gene transcription and synthesis of ET-1 precursors, and a stimulated pathway that results from rapid exocytosis of stored peptides. 9, 16, 17 Thrombin rapidly increased the release of ET-1 from aged but not young aortas, consistent with the thrombin-induced contractile responses. The stimulated release of ET-1 from aged aortas was abolished by endothelial denudation or by TAT-NSF, a cell-permeable inhibitor of NSF and endothelial exocytosis. 27, 28, 34, 35 TAT-NSF also inhibited the endothelium-dependent contraction to thrombin in aged aorta. The scrambled control peptide TAT-CON 27,28 did not significantly affect the thrombin-induced release of ET-1 or the resulting endothelium-dependent contraction occurring in aged aortas. In contrast to the stimulated release of ET-1, the basal release of the peptide, which may reflect the constitutive pathway, was not significantly different between young and aged aortas. Therefore, aged arterial endothelial cells have an increased ability to rapidly generate ET-1 through regulated exocytosis, which subsequently causes vasoconstriction of the aging vascular system. Endothelium-derived NO is an important and powerful endogenous inhibitor of endothelial exocytosis. 34 -37 However, in aged arteries, NOS inhibition did not significantly affect the release of ET-1 occurring under basal conditions or following stimulation with thrombin. An altered role of endogenous NO activity in regulating endothelial exocytosis of young and aged aortas was evident when imaging exocytosis of WPBs. VWF is the major component of WPBs and is stored as large multimers reaching an ultimate size of 20 000 kDa (ultralarge or ULVWF). 38, 39 Stimulated release of ULVWF does not occur from individual WPBs: multiple granules fuse before release and exocytosis is associated with formation of craters on the endothelial surface. 38, 40 After exocytosis, ULVWF can be unfurled by flow revealing a pearls-on-a-string appearance with adherent platelets. 41, 42 In control aged arteries, thrombin caused a significant decrease in intensity of VWF staining concomitant with the appearance of ULVWF strands and aggregates, all consistent with stimulated exocytosis of the protein. In contrast, thrombin did not alter the intensity or pattern of VWF staining in young control arteries. However, after NOS inhibition, thrombin caused the same pattern of ULVWF aggregation and release, and a decrease in VWF staining in young and aged arteries. These results suggest that endogenous NO normally restrains endothelial exocytosis in young arteries, but this restraint is diminished in aged arteries. This could reflect a generalized aging-induced decrease in endothelial NO activity. [31] [32] [33] However, although NOS inhibition did not influence thrombininduced endothelial exocytosis in aged arteries, it was an absolute requirement to observe the resulting thrombininduced ET-1-mediated constriction of these blood vessels. Although the NOS-dependent endothelium-dependent relaxation to thrombin was partly reduced in aging arteries, NOS activity was still associated with marked inhibition of contractions to phenylephrine or thrombin in aging blood vessels. This suggests that aging arteries may retain sufficient endothelial NOS activity to relax smooth muscle but not to inhibit exocytosis. Aging can cause uncoupling of NOS resulting in increased generation of reactive oxygen species (ROS) and decreased production of NO by the enzyme. 43 Altered generation of NOS-derived mediators could then contribute to differential regulation of endothelial and smooth muscle function. However, ROS such as H 2 O 2 not only mediate dilation to uncoupled NOS, 44 but also inhibit endothelial exocytosis. 45 Furthermore, catalase (1200 U/mL), which degrades H 2 O 2 , did not act like L-NAME and had no effect on constriction to -1 (red) , and nuclei (blue). Aortic segments from aged rats were incubated in the presence and absence of SM19712 followed by incubation in the presence and absence of thrombin (1 U/mL, 5 minutes). Bar: 10 m. B, Quantification of immunofluorescent images. Fluorescence intensity is expressed as a percentage of the signal in control aortas and presented as meansϮSEM (Nϭ16 to 23 scanned images for individual groups; nϭ3 animals). *Significant difference from control (***PϽ0.001); #significant difference from thrombin treated aortas (###PϽ0.001).
phenylephrine or dilation to thrombin in aged aortas (data not shown). Therefore, the most likely explanation is that exocytosis in aging endothelial cells has a reduced sensitivity to endogenous NO. Indeed, exogenous NO (DEA-NONOate) had a markedly decreased ability to inhibit endothelial exocytosis in aged compared to young arteries. Interestingly, there was no difference in the ability of exogenous NO to cause smooth muscle relaxation in young and aged arteries. These results therefore highlight a novel form of aging-induced endothelial dysfunction, namely a selective insensitivity of endothelial exocytosis to the inhibitory effects of NO. This may reflect an altered pattern of S-nitrosylation or reduced cyclic GMP signaling, which can mediate the modulatory effects of NO on endothelial exocytosis. 27, 34, 35, 46, 47 Enhanced activity of endothelial exocytosis cannot solely explain the increased ET-1 activity in aging arteries. Although NO synthase inhibition enabled exuberant thrombininduced exocytosis in young aortas, it did not uncover thrombin-induced release of ET-1 in these arteries. This indicates that in addition to enhanced exocytosis, aging also caused specific changes in endothelial ET-1 processing.
ET-1 immunofluorescence revealed diffuse punctate staining distinct from VWF suggesting that the primary storage site in native aortic endothelium is in small granules and not WPBs, which is consistent with previous studies in cultured and native endothelium. [17] [18] [19] [20] [21] [22] Under quiescent conditions, there was no significant difference in ET-1 staining between the endothelium of young and aged aortas. However, thrombin caused a dramatic and rapid increase in ET-1 staining associated with the endothelium of aged but not young arteries. These results suggest that the increased activity of ET-1 in aging arteries does not reflect increased storage of the active peptide, and that the dramatic thrombin-induced generation of ET-1 in aged arteries reflects rapid formation of ET-1. Indeed, the thrombin-induced ET-1-mediated contraction and increase in ET-1 immunofluorescent staining were markedly reduced by acute treatment of the aortas with ECE inhibitors, which would not affect ET-1 that had already been formed and stored in endothelial granules. ECE inhibition did not affect the ability of thrombin to cause exocytosis of WPBs and release of VWF. These results suggest that ET-1 is stored as a precursor and that it is formed rapidly during the exocytotic process; a process that is dramatically increased in aged compared to young endothelium. Indeed, there was increased expression of preproET-1 mRNA and also of ECE-1 mRNA in aged compared to young aortas. In each case, the increased expression was abolished by endothelium denudation indicating that it reflected a selective increase in endothelial expression. The increase in preproET-1 mRNA expression was paralleled by increased concentrations of BigET-1 in aortic lysates of aged compared to young aortas. Likewise, the functional significance of the increase in ECE-1 mRNA was demonstrated by the marked increase in phosphoramidon-sensitive contractions to exogenous BigET-1 in aged compared to young arteries. In contrast to BigET-1, exogenous ET-1 caused contraction that was similar in young and aged arteries. Therefore, the increased generation of ET-1 in aged arteries results from increased expression of endothelin precursors and converting enzyme and an increased sensitivity of the exocytotic process, compared to young arteries. Increased expression of preproET-1 and ECE-1 may result from (or be amplified by) chronic exposure to altered hemodynamics, including arterial stiffness, or altered mediator activity within the aging blood vessel wall, including diminished NO activity, increased oxidant stress and inflammatory activation of the endothelium. Altered activity of the ET-1 signaling pathway may be an important early component of the aging endothelial phenotype. Although endothelial senescence in cultured systems is associated with a loss of WPBs and ET-1 immunofluorescence, presenescent aging of cultured endothelial cells increases ET-1 expression. 48, 49 Likewise, ECE-1 expression and circulating levels of ET-1 are increased in third generation telomerase-deficient mice. 50 Human aging is associated with increased circulating levels of ET-1 and VWF. [1] [2] [3] [4] 51 Increased ET-1 production can cause oxidant stress, endothelial dysfunction, vascular inflammation, and vascular remodeling 7, 8 and likely contributes to age-related cardiovascular dysfunction including arterial stiffening and atherosclerosis. 9 -15 Likewise, VWF is an important thrombotic mediator and increased VWF levels are associated with myocardial infarction and mortality in individuals with vascular disease. 52 Increased expression of ET-1 precursors and converting enzyme and increased excitability of the exocytotic process likely contributes to increased circulating levels of these mediators and to the cardiovascular pathology of aging.
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Figure 8. Processing of ET-1 in aortas of young and aged rats. A, Quantification of
BigET-1 content of aged and young aortas determined by ELISA of aortic lysates. Data are presented as picograms per gram of aortic protein and is presented as meansϮSEM, nϭ4. **Significant difference from aged aortas (PϽ0.01). B, Contractions to BigET-1 (30 nmol/L) in aged (left) and young (right) aortas in the absence and presence of the ECE inhibitor phosphoramidon (Phos) (30 mol/L). Aortic rings were treated with the NOS inhibitor L-NAME (100 mol/L) and contracted with phenylephrine. Responses to BigET-1 were assessed after 15 minutes, expressed as a percentage change in contraction to phenylephrine and presented as meansϮSEM for nϭ6 to 7. **Significant difference from corresponding group in aged aortas (PϽ0.01); #significant difference from aortas not treated with phosphoramidon (##PϽ0.01; ###PϽ0.001). C, Expression of mRNA for preproET-1 (ppET-1), ECE-1, and ECE-2 in endothelium-containing (ϩ) and endotheliumdenuded (Ϫ) aortas from young and aged rats. mRNA was determined using real-time PCR, expressed relative to levels in aged endothelium-containing aortas, and presented as meansϮSEM for nϭ5 or 7. *Significant difference from corresponding aged aortas (endotheliumϩ or Ϫ) (**PϽ0.01; ***PϽ0.001); #significant difference from endotheliumϩ (#PϽ0.05; ###PϽ0.001).
